Aleix Prat

Sobre mí

Publicaciones destacadas

• A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

  Autores: Prat A, Tsai YH, Pascual T, Paré L, Adamo B, Vidal M, Brasó-Maristany F, Galván P, Brase JC, Rodrik-Outmezguine V, Johnston S, Ciruelos E, Parker JS .

  Referencia: Clinical Cancer Research 2020.

• Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

  Autores: Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, Escrivá-de-Romaní S, Manso L, Adamo B, Martínez E, Cortés J, Vazquez S, Perelló A, Garau I, Melé M, Martínez N, Montaño A, Bermejo B, Morales S, Echarri MJ, Vega E, González-Farré B, Martínez D, Galván P, Canes J, Nuciforo P, Gonzalez X, Prat A .

  Referencia: Clinical Cancer Research 2020.

• Immune-related adverse events of checkpoint inhibitors

  Autores: Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME .

  Referencia: Nature Reviews Disease Primers 2020.

• HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

  Autores: Schettini F; Pascual T; Conte B; Chic N; Brasó-Maristany F; Galván P; Martínez O; Adamo B; Vidal M; Muñoz M; Fernández-Martinez A; Rognoni C; Griguolo G; Guarneri V; Conte PF; Locci M; Brase JC; Gonzalez-Farre B; Villagrasa P; De Placido S; Schiff R; Veeraraghavan J; Rimawi MF; Osborne CK; Pernas S; Perou CM; Carey LA; Prat A.

  Referencia: Cancer Treatment Reviews 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Autores: Brasó-Maristany F., Griguolo G., Pascual T., Paré L., Nuciforo P., Llombart-Cussac A., Bermejo B., Oliveira M., Morales S., Martínez N., Vidal M., Adamo B., Martínez O., Pernas S., López R., Muñoz M., Chic N., Galván P., Garau I., Manso L., Alarcón J., Martínez E., Gregorio S., Gomis R.R., Villagrasa P., Cortés J., Ciruelos E., Prat A..

  Referencia: Nature Communications 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Autores: Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J .

  Referencia: Lancet Oncology 2020.

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  Autores: Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; DIeci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF.

  Referencia: Journal Of The National Cancer Institute 2020.

• A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

  Autores: Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R .

  Referencia: Annals Of Oncology 2019.

Proyectos destacados

• Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer

  Investigador/a principal: Aleix Prat Aparicio

  Financiador: IRB (Participante); Fundació La Marató de TV3 ; IDIBELL (Participante); IDIBAPS (Sede)

  Código: 201935-30-31-32

  Duración: 30/07/2020 - 29/07/2023

  Web: https://www.ccma.cat/324/15-068-252-euros-record-historic-del-marcador-final-de-la-marato-2018/noticia/2927270/

• Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

  Investigador/a principal: Aleix Prat Aparicio

  Financiador: AECC, Fundación Científica Asociación Española Contra el Cáncer ; Hospital Clinic de Baarcelona (Participante); Clínica Universidad de Navarra (Participante); Vall d'Hebron Institut d'Oncologia (Participante); HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (Partic

  Código: GCAEC19010PRAT

  Duración: 01/12/2019 - 30/11/2024

• AACR 2019 - Tailoring systemic treatment of Luminal B breast cancer

  Investigador/a principal: Patricia Galvan, Aleix Prat Aparicio

  Financiador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research

  Código: BCRF_AACR_18_001

  Duración: 01/07/2019 - 30/06/2021

• Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.

  Investigador/a principal: Aleix Prat Aparicio

  Código: 19-IO-011

  Duración: 01/07/2019 - 30/06/2021

• Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk

  Investigador/a principal: Aleix Prat Aparicio

  Financiador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Fundación Quiron Salaud ; Fundación Quirón Salud

  Código: TERAPIA_AMIGOS_18_01

  Duración: 11/02/2019 - 10/02/2022